clinical trial · NCT07389733
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.·phase2·recruiting·n = 180
Advanced Unresectable or Metastatic Breast Cancer of AdultsHRS-6208 CapsuleHRS-6209 CapsuleHRS-8080 TabletFulvestrant injectionLetrozole tablets
brief summary
This study aims to evaluate the safety, tolerability, efficacy and pharmacokinetics of HRS-6208 in combination with HRS-8080 ± HRS-6209, or in combination with fulvestrant ± HRS-6209, or in combination with letrozole ± HRS-6209 in patients with advanced unresectable or metastatic breast cancer.
started
Mar 27, 2026
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Apr 3, 2026
official title
Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HRS-6208 in Combination With HRS-8080 ± HRS-6209, or in Combination With Fulvestrant ± HRS-6209, or in Combination With Letrozole ± HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer: an Open Label, Multicenter, Phase Ib/II Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol